Results 11 to 20 of about 13,079 (188)
Pharmacokinetics of oral bromocriptine in postpartum patients
PregnancyIntroduction Cardiomyopathy is a leading cause of maternal morbidity and mortality. A prolactin fragment has been implicated in the pathogenesis, and preliminary data suggest that bromocriptine—a dopamine receptor agonist that inhibits prolactin ...
Rachel Sinkey +7 more
doaj +2 more sources
Neuroleptic Malignant Syndrome on Chronic Trifluoperazine Therapy: A Diagnostic Dilemma. [PDF]
Clin Case RepABSTRACT Neuroleptic malignant syndrome (NMS) is a rare, life‐threatening reaction to antipsychotic medication. This report describes the case of a 62‐year‐old male with chronic trifluoperazine use who presented with fever, rigidity, and altered mental status.
Baral S, Bhattarai S, Joshi KC.
europepmc +2 more sources
Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models
Translational Oncology, 2023 Chemoresistance is a major obstacle in the clinical management of metastatic, castration-resistant prostate cancer (PCa). It is imperative to develop novel strategies to overcome chemoresistance and improve clinical outcomes in patients who have failed ...
Lijuan Bai +15 more
doaj +1 more source
Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis
Frontiers in Endocrinology, 2023 ObjectiveBromocriptine treatment has been shown to reduce menstrual bleeding and pain in women with adenomyosis in a pilot clinical trial. The underlying mechanism contributing to the treatment effect is however unknown.
Yiqun Tang +9 more
doaj +1 more source
Chronically elevated sympathetic nervous system tone: A significant, common, and poorly realised contributor to cardiometabolic disease in type 2 diabetes. [PDF]
Diabetes Obes MetabDiabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1595-1598, March 2026.
DeFronzo RA.
europepmc +2 more sources
BMC Endocrine Disorders, 2020 Background Whether lower dose cabergoline therapy for hyperprolactinemia increases risk of valvular dysfunction remains controversial. We examined valvular abnormalities among asymptomatic adults with hyperprolactinemia treated with dopamine agonists ...
Amer Budayr +6 more
doaj +1 more source
THE EFFECT OF BROMOCRIPTINE ON C-REACTIVE PROTEIN IN WOMEN WITH HYPERPROLACTINEMIC AMENORRHEA [PDF]
The Medical Journal of Basrah University, 2008 C-reactive protein has become the subject of avid interest in recent years. Increased concentrations of C-reactive protein (CRP) became widely accepted as a risk factor of many inflammatory diseases including atherosclerosis, ischemic vascular diseases ...
Isam Hamo Mahmood
doaj +1 more source
Current Therapeutic Research, 2021 : Background: Although dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia, there is an identified relationship between the utilization of D2-like ...
Mohammed Fouad Shalaby, MD +5 more
doaj +1 more source
Diabetology & Metabolic Syndrome, 2023 Background Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control with drugs may reduce long-term CVD risk.
Mulualem Tesfaye Birhan +3 more
doaj +1 more source
Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis
Cancer Cell International, 2007 Background Prolactinoma is the most frequent pituitary tumor in humans. The dopamine D2 receptor agonist bromocriptine has been widely used clinically to treat human breast tumor and prolactinoma through inhibition of hyperprolactinemia and induction of ...
Huang Mu-Chiou +7 more
doaj +1 more source